trial

A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging

NCTId NCT04038957
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 22 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2023-06-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
22 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2019-08-07
Primary completion
2023-06-06
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
Ulotaront

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

1 total
London, United Kingdom

Facts & assertions

4 sourced
Enrollment
22
Phase
PHASE1
Primary Completion Date
2023-06-06
Status
COMPLETED
relationships
The graph out of here
drug
Ulotaront
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication